Print pageEmail pageRSS Feeds

News releases

The news releases listed below were believed to be accurate in all material respects at the time of original issuance. Please note that we do not intend, and assume no obligation, to update, correct, or otherwise modify any of these press releases for events that occur subsequent to the original release date. We suggest you review the more recent press releases in order to receive the most current information made available by ARIAD.

Keyword Search
 
2014 | 2013 | 2012 | 2011
DateTitle 
08/06/14ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
Conference Call Scheduled Today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2014, including revenue from sales of Iclusig® (ponatinib). The Company also provided an update on corporate developments. “We made steady progress in the second quarter on Iclusig sales in both the U.S. and Europe, and expect this ... 
Printer Friendly Version
08/05/14ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel
CAMBRIDGE, Mass. & PETACH TIKVA, Israel--(BUSINESS WIRE)--Aug. 5, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights to commercialize Iclusig® (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias. Under the terms of the agreement, ARIAD Pharmaceutic... 
Printer Friendly Version
07/16/14ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 16, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by ... 
Printer Friendly Version
07/14/14ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe
Completion Expected in October 2014 CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Jul. 14, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has provided the Company with a request for limited additional information regarding Iclusig® (ponatinib) as part of its ongoing review under the Article 20 referral p... 
Printer Friendly Version
06/23/14ARIAD Announces Three Key Appointments to Its Global Management Team
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 23, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the recent appointments of three executives with extensive pharmaceutical industry experience in the areas of global quality, medical affairs, and drug safety and pharmacovigilance. Timothy Maines, Vice President, Quality, ARIAD Pharmaceuticals, Inc. (Photo: Business Wire) Timothy Maines, Vice President, Qua... 
Printer Friendly Version
06/12/14ARIAD Announces Pricing of $200 Million Offering of 3.625% Convertible Senior Notes Due 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of $200 million aggregate principal amount of its 3.625% convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). ARIAD also granted the initial purch... 
Printer Friendly Version
06/11/14ARIAD Announces Webcast of Its Annual Shareholders Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 11, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on June 25, 2014 and can be accessed by visiting the investor relations section of the Company’s website at: http://www.ariad.com/investor. The annual meeting will take place at 10:00 a.m. (EDT) at the Company’s offices in Cambridge, Massachusetts and will include an over... 
Printer Friendly Version
06/11/14ARIAD Announces Proposed $175 Million Offering of Convertible Senior Notes Due 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 11, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019 (the “Notes”) in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the “Act”). ARIAD also... 
Printer Friendly Version
06/02/14ARIAD Announces Longer-Term Safety and Efficacy Data of Ponatinib from PACE and Phase 1 Clinical Trials
Investor Briefing and Webcast Today, June 2, at 7:30 a.m. CT CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 2, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced longer-term follow up from its Phase 1 and pivotal Phase 2 trials of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphobl... 
Printer Friendly Version
06/01/14ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors
Partial Clinical Hold of Ponatinib Lifted; Trial Resumes Enrollment of Additional Patients with GIST Investor Briefing and Webcast on Monday, June 2 at 7:30 a.m. CT CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)--Jun. 1, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced, for the first time, data from its Phase 2 trial of Iclusig® (ponatinib) in adult patients with refractory metastatic and/or unresectable gastroi... 
Printer Friendly Version
05/31/14ARIAD Announces Preliminary Safety and Efficacy Data of Ponatinib in Patients with Newly Diagnosed CML from Discontinued Phase 3 EPIC Trial
Investor Briefing and Webcast on Monday, June 2 at 7:30 a.m. CT CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 31, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced preliminary safety and efficacy data from the discontinued Phase 3 EPIC trial of Iclusig® (ponatinib) vs. imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML). These data are being featured this afternoon in a poster pre... 
Printer Friendly Version
05/31/14ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer
Investor Briefing and Webcast on Monday, June 2 at 7:30 a.m. CT CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 31, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. These study results show anti-tumor activity of AP26113 in patients with cri... 
Printer Friendly Version
05/28/14ARIAD to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 28, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will provide an overview of the Company’s business at three upcoming investor conferences: The Jefferies Global Healthcare Conference in New York City. Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will present on Wednesday, June 4 at 2:30 p.m. (ET) ... 
Printer Friendly Version
05/14/14ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2014 ASCO Annual Meeting
Company to Host Investor Meeting and Webcast on Monday, June 2 at 7:30 a.m. (CT) CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 14, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on Iclusig® (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 30 to June... 
Printer Friendly Version
05/13/14ARIAD to Present at UBS Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 13, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the UBS Global Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Tuesday, May 20, 2014, at 4:00 p.m. (ET). The ARIAD presentation will be webcast live and can be accessed by visiting the... 
Printer Friendly Version
05/07/14ARIAD Reports First Quarter 2014 Financial Results and Development Progress
Conference Call Scheduled Today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments. “As we reintroduce Iclusig into the U.S. market and continue with the European launch ... 
Printer Friendly Version
04/16/14ARIAD to Webcast Conference Call on First Quarter 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 16, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by visi... 
Printer Friendly Version
04/02/14ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 2, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D. Hugh Cole, senior vice president and... 
Printer Friendly Version
03/24/14ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 24, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. The ALTA (ALK in Lung Cancer Trial of AP26113) trial is designed to determine the safety and efficacy of AP26113 in refractory NSCLC patients who ... 
Printer Friendly Version
02/25/14ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014
Conference Call Scheduled Today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. “I am extremely pleased with the commercial and R&D progress we made in 2013, especially ending the year with Iclusig commercially available to ... 
Printer Friendly Version
02/24/14ARIAD to Present at the Cowen and Company 34th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 24, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Cowen and Company 34th Annual Health Care Conference being held in Boston. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Tuesday, March 4, at 10:40 a.m. (ET). The ARIAD presentation will be webcast live and can be accessed by vi... 
Printer Friendly Version
02/21/14ARIAD Expands Its Board of Directors with Appointment of Alexander J. Denner, Ph.D. of Sarissa Capital Management
Additional Independent Director to be Appointed to ARIAD Board CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 21, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the appointment of Alexander J. Denner, Ph.D. to a two-year term on the Company’s Board of Directors, effective immediately. With the addition of Dr. Denner, who serves as the chief investment officer and founding partner of Sarissa Capital Management LP, the Board now compr... 
Printer Friendly Version
02/19/14ARIAD to Present at the RBC Capital Markets Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 19, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Wednesday, February 26, at 3:05 p.m. (ET). The ARIAD presentation at the RBC Capital Markets Healthcare Conference ... 
Printer Friendly Version
02/10/14ARIAD to Host Conference Call and Webcast Discussion of Fourth Quarter and Year-End 2013 Financial Results on February 25, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its fourth quarter and year-end 2013 financial results on Tuesday, February 25, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcas... 
Printer Friendly Version
02/05/14ARIAD to Present at the Leerink Swann Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Leerink Swann Global Healthcare Conference being held in New York City. Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will provide an overview of the Company’s business on Wednesday, February 12, at 11:05 a.m. (ET). The ARIAD presentation at the Leerink Sw... 
Printer Friendly Version
01/28/14ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Australia
CAMBRIDGE, Mass. & MELBOURNE, Australia--(BUSINESS WIRE)--Jan. 28, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), a specialty pharmaceutical company, today announced that ARIAD has granted STA exclusive rights to commercialize Iclusig® (ponatinib) in Australia in patients with Philadelphia-positive (Ph+) leukemias. Under the terms of the agreement, STA will be responsible for obt... 
Printer Friendly Version
01/17/14ARIAD Announces the Commercial Availability of Iclusig (Ponatinib) for Patients with Refractory Philadelphia-Positive Leukemias in the U.S.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 17, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the commercial availability of Iclusig® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and... 
Printer Friendly Version
01/14/14ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme™ Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease
CAMBRIDGE, Mass. & TEL AVIV, Israel--(BUSINESS WIRE)--Jan. 14, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medinol, Ltd. today announced the initiation of two registration trials of Medinol’s NIRsupremeTM Ridaforolimus-Eluting Coronary Stent System incorporating ARIAD’s mTOR inhibitor, ridaforolimus. The two NIRsupreme clinical trials are randomized, single-blind, global studies taking place in the United States, Europe, Israel and C... 
Printer Friendly Version
01/13/14Biologics Selected by ARIAD to Be the Exclusive Specialty Pharmacy Provider for Iclusig (ponatinib)
January 13, 2014 07:30 AM Eastern Standard Time CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc., an integrated oncology services company, is pleased to announce that it has been selected by ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) to be the sole specialty pharmacy provider of Iclusig® (ponatinib) and manager of its Patient Access and Support Services (ARIAD PASSTM) program. Iclusig is a treatment for adult patients with refractory chronic myeloid leukemia or Philadelphia-chromosome positive (... 
Printer Friendly Version
01/02/14ARIAD to Present at the 32nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 32nd Annual J.P. Morgan Healthcare Conference being held in San Francisco. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Tuesday, January 14 at 3:00 p.m. (PT). The ARIAD presentation at the J.P. Morgan Healthcare Conference will be ... 
Printer Friendly Version
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue